

Meet AZN Management: ASCO

Investor Event – Faculty Biographies

1 June 2026

Pascal Soriot

Chief Executive Officer

Pascal is Executive Director and Chief Executive Officer at AstraZeneca. He has been a member of the Board and CEO since October 2012. Pascal has a passion for science and medicine as well as a successful track record of managing change, executing strategy and leading a diverse organisation.

Prior to AstraZeneca, Pascal served as COO of Roche's pharmaceuticals division from 2010 to 2012 and previously as CEO of Genentech where he led its successful merger with Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior roles in numerous major companies around the world. He is a Doctor of Veterinary Medicine and holds an MBA from HEC Paris.

Pascal received a British knighthood for services to life sciences and leadership in the global response to the COVID pandemic in the Queen's Birthday Honours 2022. He is also on the board of the Sustainable Markets Initiative and champions the Health Systems Task Force which aims to accelerate the delivery of net zero, sustainable healthcare.

Dave Fredrickson

Executive Vice President, Oncology Haematology Business

Dave was appointed Executive Vice-President, Oncology Haematology Business Unit in October 2017 and is responsible for driving growth and maximising the global commercial performance of the AstraZeneca global Oncology portfolio.

Previously, Dave served as President of AstraZeneca Japan and Vice-President, Specialty Care in the US. While in Japan, Dave also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations Japan and was a Director of the Japan Pharmaceutical Manufacturers Association.

Before joining AstraZeneca, Dave worked at Roche/Genentech, where he served in several functions and leadership positions. Prior to this, Dave worked at the Monitor Group, now Monitor Deloitte Group, a global strategy consultancy.

Dave is a graduate of Georgetown University in Washington DC.

Susan Galbraith

Executive Vice President, Oncology Haematology R&D

Susan was appointed as Executive Vice President, Oncology Haematology Research & Development in July 2021, with responsibility for transforming the productivity and scientific output from Oncology R&D. Over her career, Susan has helped develop 12 approved medicines.

As a clinical oncologist, Susan studied medicine at Manchester and Cambridge Universities and has a PhD from the University of London. In recognition of her contributions to Oncology drug development, she has been awarded an honorary Doctorate of Medical Science from the Institute of Cancer Research, is a Fellow of the Academy of Medical Sciences and elected to the Academy of the American Association for Cancer Research.

Susan is a member of the Cambridge Cancer Centre Executive Committee and the Scientific Advisory Board of the ICR. From 2021 to 2024, she also served on the Board of Directors of the AACR and currently serves on the European Association of Cancer Research Advisory Council.

Gianluca Pirozzi

SVP, Head of Development, Regulatory & Safety, Rare Disease

Gianluca joined Alexion in October 2019 and currently leads the company's integrated Development, Regulatory and Safety organisation. Previously, he served in various roles at Sanofi Genzyme, including Head of Development for Rare Diseases and Gene Therapy. He has served on the Board of Directors of Imbria Pharmaceuticals for two years, and is currently Board Member of Timber Pharmaceuticals, as well as scientific advisor for the Smith-Magenis Syndrome Research Foundation.

Gianluca holds an MD degree from University Campus Bio-Medico and a PhD in Immunology from Sapienza University, both in Rome, Italy, and completed a Post Doctoral Research Fellowship in Immunology at the Pasteur Institute in Paris, France.

Ghassan Abou-Alfa

Attending Physician and Professor at Memorial Sloan Kettering Cancer Center

Ghassan Abou-Alfa, MD, obtained his degrees in Biology and Medicine from the American University in Beirut and pursued postdoctoral training in medical oncology and haematology at Yale School of Medicine. His focus on gastrointestinal cancers developed during this period, shaping his career as a specialised Gastrointestinal Medical Oncologist with a particular emphasis on primary liver cancer (hepatocellular carcinoma), at Memorial Sloan Kettering Cancer Center, New York. He also works as a Professor of Medicine at Weill Medical School, Cornell University in New York, and as an Adjunct Professor of Clinical Medicine at Trinity College, Dublin.

In addition to his medical qualifications, Prof. Abou-Alfa holds a Master's of Business Administration from Columbia University, New York, complementing his clinical expertise with a robust understanding of healthcare management and leadership and completed a JD degree from Fordham Law School, advancing his global medical diplomacy efforts. He leads the National Cancer Institute Hepatobiliary Task Force and serves on the NCI AIDS Malignancy Consortium Steering Committee.